Project Grant R01HL182688
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $749K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Phoenix, AZ 85004, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $108,950 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoplatforms for co-delivery of drugs and genes to protect lung endothelium from neonatal and pediatric lung injury. The recipient will optimize nanoparticle formulations for stability, safety, and endothelial targeting in neonatal lungs, characterizing physicochemical properties that influence targeting...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $781,860 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of neutrophils in mediating endothelial regeneration and vascular repair in sepsis and acute respiratory distress syndrome (ARDS). The research addresses ARDS pathology, specifically endothelial barrier injury and increased vascular...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Heart, Lung, and Blood Institute awarded $448,250 to The Research Foundation For The State University Of New York on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger RNA therapy for acute respiratory distress syndrome. The award funds development of an IL-10 mRNA therapeutic delivered via sulfonium lipid nanoparticles, a novel lung-targeting technology designed to suppress...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Washington University $635,247 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of resolution-phase neutrophils in acute respiratory distress syndrome (ARDS) recovery. The project tests the hypothesis that neutrophils activate counter-regulatory mechanisms, including expression of 15-lipoxygenase (15-LO), in lung tissue following acute injury to...
- The National Heart, Lung, and Blood Institute awarded The Research Foundation for the State University of New York $502,773 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate docosahexaenoic acid (DHA)-loaded nanoparticles as an inflammation resolution therapy targeting acute lung injury and acute respiratory distress syndrome. The research addresses the clinical challenge that anti-inflammatory agents—the current standard approach to...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Duke University $2,023,862 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL170175) to develop and validate predictive models of acute respiratory distress syndrome (ARDS) using protein biomarkers and clinical data, and to identify resilience markers and endotypes associated with ARDS recovery through an integrated multiomics pipeline. The project, titled "Resilience...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $778,582 on August 15, 2026, to identify genetic variants that perturb gene regulatory responses to athero-protective and athero-prone hemodynamic waveforms in human endothelial cells. The award funds research under the Cardiovascular Diseases Research program (CFDA 93.837). The project investigates how natural genetic variation governs endothelial cell responses to hemodynamic shear stress from blood flow, with...
- The National Heart, Lung, and Blood Institute awarded the University of Georgia Research Foundation, Inc. $588,284 on August 1, 2026, to investigate long noncoding RNA regulation in complement-mediated endothelial barrier disruption as a potential therapeutic strategy for acute lung injury and acute respiratory distress syndrome. Award R01HL178801 is funded under the Cardiovascular Diseases Research program (CFDA 93.837), a Project Grant. The research addresses the persistent 30–40% mortality...